(0.16%) 5 162.75 points
(0.15%) 38 890 points
(0.10%) 18 020 points
(0.82%) $78.75
(0.33%) $2.15
(0.61%) $2 322.60
(2.10%) $27.25
(0.13%) $966.60
(0.04%) $0.929
(-0.14%) $10.86
(-0.08%) $0.796
(0.20%) $91.63
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
0.00% HKD 9.20
Live Chart Being Loaded With Signals
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 500.00 |
Średni wolumen | 9 910.00 |
Kapitalizacja rynkowa | 4.41B |
Następna data zysków | ( HKD0 ) 2024-05-08 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -7.13 |
ATR14 | HKD0 (0.00%) |
Jiangsu Recbio Technology Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Jiangsu Recbio Technology Finanse
Annual | 2023 |
Przychody: | HKD30.38M |
Zysk brutto: | HKD22.34M (73.54 %) |
EPS: | HKD-1.190 |
FY | 2023 |
Przychody: | HKD30.38M |
Zysk brutto: | HKD22.34M (73.54 %) |
EPS: | HKD-1.190 |
FY | 2022 |
Przychody: | HKD5.33M |
Zysk brutto: | HKD5.33M (100.00 %) |
EPS: | HKD-1.520 |
FY | 2021 |
Przychody: | HKD0.00 |
Zysk brutto: | HKD0.00 (0.00 %) |
EPS: | HKD-1.372 |
Financial Reports:
No articles found.
Jiangsu Recbio Technology
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej